Evidence map›Paper›PMID 41221290›Full record

ArticleFrontiers in immunology2025

Effects of Long-term low-dose intermittent rapamycin administration on glucose metabolism and immune system of SAMP8 and SAMR1 mice.

Luiz Adriano Damasceno Queiroz, Rafael Santos Barros, Josiane Betim Assis, Camille Cristine Caldeira Silva, Walter Miguel Turato, Sofia Xavier Bustia, Stephen Fernandes Rodrigues, Anderson Sá-Nunes, Joilson O Martins

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Luiz Adriano Damasceno QueirozLaboratory of Immunoendocrinology, Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences - São Paulo University, São Paulo, Brazil.
Rafael Santos BarrosLaboratory of Immunoendocrinology, Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences - São Paulo University, São Paulo, Brazil.
Josiane Betim AssisLaboratory of Experimental Immunology, Department of Immunology, Institute of Biomedical Sciences - São Paulo University, São Paulo, Brazil.
Camille Cristine Caldeira SilvaEnergy Metabolism Laboratory, Department of Biochemistry, Institute of Chemistry - University of Sao Paulo, São Paulo, Brazil.
Walter Miguel TuratoMulti-User Preclinical Imaging Center, Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences - São Paulo University, São Paulo, Brazil.
Sofia Xavier BustiaLaboratory of Immunoendocrinology, Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences - São Paulo University, São Paulo, Brazil.
Stephen Fernandes RodriguesLaboratory of Vascular Nanopharmacology, Department of Pharmacology, Institute of Biomedical Sciences of University - Sao Paulo, Sao Paulo, Brazil.
Anderson Sá-NunesLaboratory of Experimental Immunology, Department of Immunology, Institute of Biomedical Sciences - São Paulo University, São Paulo, Brazil.
Joilson O MartinsLaboratory of Immunoendocrinology, Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences - São Paulo University, São Paulo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aging involves a gradual decline in physiological integrity, and rapamycin (RAPA) has demonstrated potential as an anti-aging agent. Nonetheless, its effects on glucose metabolism and immune function may vary based on dosage and administration regimen. This study investigates the impact of intermittent low-dose RAPA on glucose metabolism and immune function in Senescence-Accelerated Mouse Prone 8 (SAMP8) and Senescence-Accelerated Mouse Resistant 1 (SAMR1) mice. Twelve-week-old male SAMP8 and SAMR1 mice were treated with RAPA (0.78 µg/kg) every five days for six months. Glucose uptake, mitochondrial respiratory capacity, spleen and thymus immunophenotype, lymphoproliferation, and cytokine profiles were evaluated. Our findings indicate that RAPA reduced glucose uptake in the bladder and the percentage of FoxP3

Indexed as

AgingGlucoseImmune SystemSirolimusAnimalsCytokinesEnergy MetabolismMaleMiceMitochondriaSpleenThymus GlandCytokinesGlucoseSirolimusimmunosenescencemitochondriarapamycinSAMP8SAMR1

Identifiers

PMID41221290
PMCPMC12598397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.